Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -2.68%33 Price-to-Tangible-Book is 0.47 as of Aug. 20, 2026, which is 73% below its 10-year median of 1.73. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 698 Medical Devices & Instruments companies, Standard BioTools ranks better than 95.85% on this metric.
The historical rank and industry rank for Standard BioTools's Price-to-Tangible-Book or its related term are showing as below:
LAB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.46 Med: 1.73 Max: 1857.5
Current: 0.47
During the past 13 years, Standard BioTools's highest Price to Tangible Book Ratio was 1857.50. The lowest was 0.46. And the median was 1.73.
LAB's Price-to-Tangible-Book is ranked better than 95.85% of 698
companies
in the Medical Devices & Instruments industry
Industry Median: 2.7
vs LAB: 0.47
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Standard BioTools Price-to-Tangible-Book Related Terms
Standard BioTools Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LAB vs CV, ELMD, CATX: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Standard BioTools's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Standard BioTools (LAB) has a Price-to-Tangible-Book of 0.47 as of Aug. 20, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Standard BioTools and its competitors. This is 73% below median its historical median of 1.73. Over the past decade, Standard BioTools' Price-to-Tangible-Book has ranged from 0.46 to 1,857.50. According to the industry distribution chart, Standard BioTools ranks #29 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 4.2%.
Is Standard BioTools' Price-to-Tangible-Book too high?
Standard BioTools' current Price-to-Tangible-Book of 0.47 is 73% below median its 10-year median of 1.73. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 1,857.50. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.70. Standard BioTools' value of 0.47 is 82.6% below this industry median. Based on the distribution chart, Standard BioTools ranks #29 out of 698 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Price-to-Tangible-Book compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #29 out of 698 companies for Price-to-Tangible-Book. This places Standard BioTools in the top 4% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 2.70. Standard BioTools' value of 0.47 is 82.6% below this benchmark. Historically, Standard BioTools' own Price-to-Tangible-Book has ranged from 0.46 to 1,857.50 over the past decade. While the company's 10-year median is 1.73 vs. the industry median of 2.70, Standard BioTools has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.70, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Price-to-Tangible-Book of 0.47 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Price-to-Tangible-Book is 0.47, which is 73% below median its own 10-year median of 1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 7.9% below its estimated fair value. The current Price-to-Tangible-Book is 0.47, which is 73% below median its 10-year median of 1.73 and 82.6% below the Medical Devices & Instruments industry median of 2.70. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Standard BioTools (LAB), the current Price-to-Tangible-Book is 0.47 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 7.9% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Fairly Valued.
Key valuation signals for LAB:
Price-to-Tangible-Book: 0.47 (73% below median its 10-year median of 1.73)
GF Value™: $0.71 vs. price of $0.65 (7.9% below fair value)
Industry Position: 82.6% below the Medical Devices & Instruments median (#29 of 698)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
